ASCIA News

  • CFAR Hot Publications
    The Centre for Food & Allergy Research (CFAR) Hot Publications session is being held on Wednesday 31 August 2022, 11.30-13.00 AEST, as part of the ASCIA 2022 Conference in Melbourne.  This session features brief oral presentations summarising food allergy research that has...
  • World Allergy Week 2022
    The theme for World Allergy Week 2022 (5 to 11 June) is respiratory allergic diseases, including asthma. The importance of the connection between allergic airway diseases and asthma is reflected in the ASCIA 2022 Conference program and ASCIA online resources:   The ASCIA...
  • Autoinflammatory Disease Symposium
    The 2nd Australian Autoinflammatory Disease Symposium is being hosted by the Walter and Eliza Hall Institute (WEHI) on Monday 29 August 2022, prior to the ASCIA 2022 Conference in Melbourne. This symposium will facilitate discussion of autoinflammatory diseases, spanning...
  • Influenza vaccination and allergy
    People with egg allergy may be safely vaccinated with the influenza (flu) vaccine.  Information about Influenza vaccination and egg allergy is available on the ASCIA website https://www.allergy.org.au/patients/food-allergy/egg-allergy-flu-vaccine  People with mammalian meat...
  • Support for people with primary immunodeficiencies
    The ASCIA Immunodeficiency Strategy for Australia and New Zealand aims to enhance the important work of organisations that support  people with primary immunodeficiencies and their carers, and enable key issues to be addressed, including early diagnosis and improved access...
  • Jorveza® is PBS listed for treatment of EoE
    Jorveza® (budesonide) is an orally disintegrating tablet for the treatment of eosinophilic oesophagitis (EoE) in adults, that was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 May 2022. Jorveza represents the first TGA approved and PBS subsidised medication for...
  • HAE Day - Monday 16 May 2022
    Hereditary Angioedema, commonly known as HAE, has been classified as a complement deficiency, which is a type of primary immunodeficiency, and occurs in around one in 50,000 people.  People with HAE have unpredictable, recurrent and rapid swellings, which may involve the...
  • Paxlovid® is PBS listed for treatment of COVID-19
    Paxlovid® (nirmatrelvir/ritonavir tablets) is listed on the Pharmaceutical Benefits Scheme (PBS) from 1 May 2022, as a treatment for COVID-19. Adults can be prescribed PBS-subsidised Paxlovid® by their doctor or nurse practitioner if they have mild to moderate COVID-19...
ASCIA Member Login

Site last updated: 26 June 2022
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...

Join our mailing list here...

AIFA: Donate Now
AIFA: Donate Now
National Allergy Strategy
National Allergy Strategy
ASCIA: WAO Member
ASCIA: WAO Member
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.